Regeneron Pharmaceuticals Inc is a leading biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. The company's mission is to leverage its proprietary technologies and scientific expertise to create transformative therapies that improve patient outcomes. Regeneron's strategy emphasizes a robust pipeline of biologic drugs, particularly in the fields of ophthalmology, immunology, and oncology. Through strategic collaborations and a commitment to research and development, Regeneron aims to address unmet medical needs and enhance the quality of life for patients worldwide.

REGENERON PHARMACEUTICALS INC

Regeneron Pharmaceuticals, in collaboration with Sanofi, has received exciting news regarding its drug Dupixent (dupilumab). The FDA has accepted their supplemental Biologics License Application for Priority Review to treat adults suffering from bullous pemphigoid, a severe chronic skin condition. If the application is approved, which is anticipated by June 20,...

Regeneron's Dupixent Receives FDA Priority Review for Bullous Pemphigoid Treatment, Potential First Targeted Therapy in the U.S.

Regeneron and Sanofi's Dupixent is on the brink of becoming the first targeted therapy for bullous pemphigoid in the U.S., with the FDA's Priority Review designation highlighting its potential impact. Could this groundbreaking treatment reshape the landscape for patients with severe skin conditions?